EFFECT OF NOCTURNAL HYPOTENSION AND INTROCULAR PRESSURE ON NOCTURNAL

夜间低血压和眼压对夜间的影响

• 批准号: 6291038
• 负责人: ALON HARRIS
• 金额: $ 1.7万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6291038
• 关键词: adrenergic agents; beta antiadrenergic agent; blood pressure; cardiac output; clinical research; clinical trials; drug adverse effect; drug screening /evaluation; glaucoma; heart rate; human subject; human therapy evaluation; hypotension; intraocular pressure; pathologic process; vision

The present study will evaluate the effects of a nonselective beta- blocking agent, timolol, versus a beta-blocker with intrinsic sympathomimetic activity (ISA), carteolol, on the variation of nocturnal blood pressure, nocturnal cardiac output, nocturnal intraocular pressure (IOP) and visual function. Recent evidence has shown that a high percentage of primary open angle glaucoma (POAG) patients have unusual variations in both blood pressure and IOP. Topical beta antagonist agents are the drugs of first choice for lowering IOP in POAG patients. Although the systemic side effects of these agents are well established, ie reduction in heart rate, blood pressure, etc, they have been generally ignored because systemic cardiovascular factors have not been considered important for the pathogenesis of the disease. However, if various beta- blocker drugs have substantially different effects on cardiovascular factors which in turn influence the progression of the disease, selection of a treatment regiment must include a more critical review of each drug's systemic side effects.

本研究将评估非选择性β- 阻断剂噻吗洛尔与β-受体阻滞剂 拟交感神经活性（伊萨），卡替洛尔，对夜间 血压，夜间心输出量，夜间眼内压 (IOP)和视觉功能。最近的证据表明， 原发性开角型青光眼（POAG）患者中， 血压和IOP的变化。 局部β拮抗剂 是POAG患者降眼压的首选药物。 虽然 这些药物的全身性副作用是公认的， 降低心率、血压等， 由于未考虑全身性心血管因素而被忽略 对疾病的发病机制很重要。 但是，如果各种β- 阻断剂药物对心血管疾病的影响 这些因素反过来影响疾病的进展，选择 必须包括对每种药物的更严格的审查， 全身副作用